
1. chembiochem. 2018 feb 2;19(3):272-279. doi: 10.1002/cbic.201700428. epub 2017 dec
18.

new ws9326a derivatives one new annimycin derivative antimalarial
activity produced streptomyces asterosporus dsm 41452 mutant.

zhang s(1), zhu j(1), zechel dl(2), jessen-trefzer c(1), eastman rt(3), paululat 
t(4), bechthold a(1).

author information: 
(1)department pharmaceutical biology biotechnology, university of
freiburg, stefan-meier-strasse 19 vf, 79104, freiburg im breisgau, germany.
(2)department chemistry, queen's university, 90 bader lane, kingston, ontario,
k7l 3n6, canada.
(3)division pre-clinical innovation, national center advancing
translational sciences/nih, 9800 medical center drive, rockville, md, 20850, usa.
(4)department chemistry biology, universität siegen,
adolf-reichwein-strasse 2, 57068, siegen, germany.

in study, report streptomyces asterosporus dsm 41452 producer
of new molecules related nonribosomal cyclodepsipeptide ws9326a the
polyketide annimycin. s. asterosporus dsm 41452 shown produce six
cyclodepsipeptides peptides, ws9326a g. notably, compounds ws9326f and
ws9326g described before. genome s. asterosporus dsm 41452
was sequenced, putative ws9326a gene cluster identified. gene-deletion 
experiments confirmed cluster responsible biosynthesis of
ws9326a g. additionally, gene-deletion experiment demonstrated sas16
encoding cytochrome p450 monooxygenase involved synthesis the
novel (e)-2,3-dehydrotyrosine residue found ws9326a derivatives. an
insertion mutation within putative annimycin gene cluster led the
production new annimycin derivative, annimycin b, exhibited modest
inhibitory activity plasmodium falciparum.

© 2018 wiley-vch verlag gmbh & co. kgaa, weinheim.

doi: 10.1002/cbic.201700428 
pmcid: pmc6324189
pmid: 29148157  [indexed medline]

